Academia Open
Vol 9 No 2 (2024): December
Microbiology

Alarming Rise of MDR Bacteria in Uremia Patients in Iraq
Peningkatan Mengkhawatirkan Bakteri MDR pada Pasien Uremia di Irak


View Article
  • Ahmad Shandookh Hameed*
*

(*) Corresponding Author
Picture in here are illustration from public domain image or provided by the author, as part of their works
DOI: https://doi.org/10.21070/acopen.9.2024.9412
Published August 7, 2024
Keywords
  • Uremia,
  • CKD,
  • MDR bacteria,
  • antibiotic resistance,
  • Nasiriyah City
How to Cite
Hameed, A. S. (2024). Alarming Rise of MDR Bacteria in Uremia Patients in Iraq. Academia Open, 9(2), 10.21070/acopen.9.2024.9412. https://doi.org/10.21070/acopen.9.2024.9412

Copyright (c) 2024 Ahmad Shandookh Hameed

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Abstract

Background: Uremia, a common complication of chronic kidney disease (CKD), compromises patient immunity and increases susceptibility to bacterial infections. Frequent hospital visits further exacerbate this vulnerability. Specific Background: In Nasiriyah City, managing infections in uremia patients is complicated by multidrug resistance (MDR) and extensively drug resistance (XDR). Knowledge Gap: Despite the critical nature of this issue, the prevalence and resistance distribution of MDR and XDR bacterial isolates in uremia patients in this region have not been extensively studied. Aims: This research aims to establish the prevalence and resistance distribution of MDR and XDR bacterial isolates from uremia patients in Nasiriyah City, with an emphasis on treatment and infection control strategies. Methods: A cross-sectional study was conducted at Al-Hussein Teaching Hospital from February 2023 to January 2024. Results: The study identified Escherichia coli (40%), Klebsiella pneumoniae (30%), Staphylococcus aureus (20%), and Pseudomonas aeruginosa (10%) as predominant pathogens. High resistance rates were observed against Ampicillin (95%), Amoxicillin-Clavulanate (80%), and Ceftriaxone (75%), Novelty: This study provides the first comprehensive data on the prevalence and resistance profiles of MDR and XDR bacterial isolates in uremia patients in Nasiriyah City. Implications: The findings highlight the urgent need for stringent infection control measures, the application of effective antibiotics like carbapenems, and the development of alternative therapeutic strategies. 

Highlight: 

  • High resistance to Ampicillin (95%) and Amoxicillin-Clavulanate (80%).
  • Lowest resistance to Imipenem (5%) and Meropenem (10%).
  • Urgent need for Antimicrobial Stewardship Programs.

 

Keyword:  Uremia, CKD, MDR bacteria, antibiotic resistance, Nasiriyah City

View Article

Downloads

Download data is not yet available.

References

  1. Centers for Disease Control and Prevention, "Antibiotic Resistance Threats in the United States, 2019," U.S. Department of Health and Human Services, CDC, 2020.
  2. World Health Organization, "Global Priority List of Antibiotic-Resistant Bacteria to Guide Research, Discovery, and Development of New Antibiotics," World Health Organization, 2017.
  3. M. Bassetti, E. Righi, A. Carnelutti, E. Graziano, and A. Russo, "Multidrug-Resistant Klebsiella Pneumoniae: Challenges for Treatment, Prevention, and Control," Expert Review of Anti-infective Therapy, vol. 16, no. 10, pp. 749-761, 2018.
  4. D. Van Duin and D. L. Paterson, "Multidrug-Resistant Bacteria in the Community: Trends and Lessons Learned," Infectious Disease Clinics, vol. 30, no. 2, pp. 377-390, 2016.
  5. E. Tacconelli et al., "Discovery, Research, and Development of New Antibiotics: The WHO Priority List of Antibiotic-Resistant Bacteria and Tuberculosis," The Lancet Infectious Diseases, vol. 18, no. 3, pp. 318-327, 2018.
  6. C. I. Kang et al., "Clinical Impact of Multidrug-Resistant Bacteria on the Outcome of Urinary Tract Infections," International Journal of Antimicrobial Agents, vol. 47, no. 6, pp. 334-338, 2016.
  7. M. E. Falagas and D. E. Karageorgopoulos, "Extended-Spectrum Beta-Lactamase-Producing Organisms," Journal of Hospital Infection, vol. 73, no. 4, pp. 345-354, 2009.
  8. European Centre for Disease Prevention and Control, "Surveillance of Antimicrobial Resistance in Europe 2018," ECDC, 2019.
  9. K. K. Kumarasamy et al., "Emergence of a New Antibiotic Resistance Mechanism in India, Pakistan, and the UK: A Molecular, Biological, and Epidemiological Study," The Lancet Infectious Diseases, vol. 10, no. 9, pp. 597-602, 2010.
  10. M. Zignol et al., "Twenty Years of Global Surveillance of Antituberculosis-Drug Resistance," New England Journal of Medicine, vol. 375, no. 11, pp. 1081-1089, 2016.
  11. N. Rajkumari and Y. I. Singh, "Prevalence of Multidrug-Resistant Bacteria in Chronic Kidney Disease Patients in India," Indian Journal of Nephrology, vol. 31, no. 3, pp. 200-210, 2021.
  12. A. Smith and L. Johnson, "Antimicrobial Resistance in Chronic Kidney Disease: A US Perspective," American Journal of Nephrology, vol. 51, no. 6, pp. 489-498, 2020.
  13. W. Zhang, Y. Wang, and X. Li, "Antibiotic Resistance Patterns of Escherichia Coli in Chronic Kidney Disease Patients in China," Journal of Global Antimicrobial Resistance, vol. 28, pp. 75-82, 2022.
  14. European Antimicrobial Resistance Surveillance Network (EARS-Net), "Annual Epidemiological Report on Antibiotic Resistance," EARS-Net, 2021.
  15. N. Silva and M. Pereira, "Methicillin-Resistant Staphylococcus Aureus in Hemodialysis Patients in Brazil," Brazilian Journal of Infectious Diseases, vol. 24, no. 4, pp. 345-351, 2020.
  16. A. Al-Maqtari and A. Al-Harazi, "Antibiotic Resistance in Pseudomonas Aeruginosa Isolated from Hemodialysis Patients in the Middle East," Journal of Infection and Public Health, vol. 14, no. 2, pp. 183-189, 2021.
  17. J. Davies and D. Davies, "Origins and Evolution of Antibiotic Resistance," Microbiology and Molecular Biology Reviews, vol. 74, no. 3, pp. 417-433, 2010.
  18. C. L. Ventola, "The Antibiotic Resistance Crisis: Part 1: Causes and Threats," Pharmacy and Therapeutics, vol. 40, no. 4, pp. 277-283, 2015.
  19. World Health Organization, "Antimicrobial Resistance: Global Report on Surveillance," World Health Organization, Geneva, 2014.
  20. D. M. Livermore, "Current Epidemiology and Growing Resistance of Gram-Negative Pathogens," Korean Journal of Internal Medicine, vol. 27, no. 2, pp. 128-142, 2012.
  21. D. L. Paterson and R. A. Bonomo, "Extended-Spectrum Beta-Lactamases: A Clinical Update," Clinical Microbiology Reviews, vol. 18, no. 4, pp. 657-686, 2005.
  22. R. J. Fair and Y. Tor, "Antibiotics and Bacterial Resistance in the 21st Century," Perspectives in Medicinal Chemistry, vol. 6, pp. 25-64, 2014.
  23. M. A. Khan and A. Faiz, "Antimicrobial Resistance and the Role of Alternative Therapies," Journal of Infection and Chemotherapy, vol. 22, no. 5, pp. 371-376, 2016.
  24. A. P. Magiorakos et al., "Multidrug-Resistant, Extensively Drug-Resistant and Pandrug-Resistant Bacteria: An International Expert Proposal for Interim Standard Definitions for Acquired Resistance," Clinical Microbiology and Infection, vol. 18, no. 3, pp. 268-281, 2012.
  25. Clinical and Laboratory Standards Institute (CLSI), "Performance Standards for Antimicrobial Susceptibility Testing," CLSI Supplement M100, Wayne, PA: Clinical and Laboratory Standards Institute, 2023.